Previous Close | 3.9600 |
Open | 3.9809 |
Bid | 3.4700 x 1300 |
Ask | 5.9700 x 900 |
Day's Range | 3.8287 - 4.0550 |
52 Week Range | 2.3300 - 6.7000 |
Volume | |
Avg. Volume | 38,325 |
Market Cap | 47.177M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.2340 |
Earnings Date | Mar 22, 2023 - Mar 27, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 8.50 |
Subscribe to Yahoo Finance Plus to view Fair Value for GANX
Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day January Micro-Cap Conference taking place Wednesday and Thursday, January 18-19, 2023.
BETHESDA, Md., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule treatments, today announced that Matthias Alder, CEO, will present a corporate update at the Sidoti Small-Cap Virtual Investor Conference on Wednesday, January 18 at 2:30 PM ET. A webcast of the presentation
Gain Therapeutics, Inc. (GANX) delivered earnings and revenue surprises of 17.39% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?